进行经导管二尖瓣修复术（TMVR）的患者中，癌症病史常见。本研究旨在研究癌症病史对TMVR后结局的影响。评估了来自单中心前瞻性登记的TMVR病历纪录中患者的癌症病史，并研究了癌症病史与六周功能结局及随访中的临床结局之间的关联，随访中位数为594天。共有661位患者（平均年龄79岁；年龄范围37-101岁；男性占56.1%）参与研究，其中21.6%有癌症病史，且4.1%患者病情活跃。与非癌症患者相比，癌症患者的手术成功率相似（二尖瓣反流减轻至2级或更低的比例分别为91.6%和88%；p = 0.517），且6分钟步行距离、纽约心功能分级、明尼苏达心力衰竭共患者问卷得分和简明版36项短表得分也有相似的改善。癌症患者与非癌症患者的1年生存率（分别为83%和82%；p = 0.813）和1年免心力衰竭失控生存率（分别为75%和76%；p = 0.871）相似。患有活跃癌症的患者与有癌症病史的患者相比，死亡率显著升高（风险比为2.05 [95% CI 1.11-3.82；p = 0.023]），但1年的里程碑分析显示其死亡率相似。TMVR在癌症患者和无癌症患者以及有症状的二尖瓣反流方面具有相等的疗效。癌症患者的临床结果及短期功能改善与非癌症患者相似。然而，癌症患者的长期死亡率增加，强调心脏团队在选择患者时的重要性。© 2023. 作者

History of cancer is common in patients undergoing transcatheter mitral valve repair (TMVR).Aim was to examine the impact of cancer history on outcomes after TMVR.In patients of a monocentric prospective registry of TMVR history of cancer was retrospectively assessed from records. Associations with 6-week functional outcomes and clinical outcomes during a median follow-up period of 594 days were examined.Of 661 patients (mean age 79 years; age-range 37-101 years; 56.1% men), 21.6% had a history of cancer with active disease in 4.1%. Compared with non-cancer patients, cancer patients had a similar procedural success rate (reduction of mitral regurgitation to grade 2 or lower 91.6% vs. 88%; p = 0.517) and similar relevant improvement in 6-min walking distance, NYHA class, Minnesota Living with Heart Failure Questionnaire score and Short Form 36 scores. 1-year survival (83% vs. 82%; p = 0.813) and 1-year survival free of heart failure decompensation (75% vs. 76%; p = 0.871) were comparable between cancer and non-cancer patients. Patients with an active cancer disease showed significantly higher mortality compared with patients having a history of cancer (hazard ratio 2.05 [95% CI 1.11-3.82; p = 0.023]) but similar mortality at landmark analysis of 1 year.TMVR can be performed with equal efficacy in patients with and without cancer and symptomatic mitral regurgitation. Cancer patients show comparable clinical outcome and short-term functional improvement as non-cancer patients. However, longterm mortality was increased in patients with active cancer underlining the importance of patient selection within the heart-team evaluation.© 2023. The Author(s).